Don't Expect the New Anticoagulant Betrixaban to be Added to Your Formulary

March 2018

You'll hear buzz about betrixaban (Bevyxxa, beh-VYKE-sah), a new direct oral anticoagulant (DOAC) for extended VTE prophylaxis.

We know extending VTE prophylaxis after discharge is helpful for certain high-risk surgical patients...such as after hip or knee surgery. But the bleeding risk outweighs the benefit in most other patients.

Now betrixaban will be promoted for VTE prophylaxis in MEDICAL inpatients...and after discharge for up to 6 weeks total duration.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote